 Connection
Christina Aquilante to Anticoagulants
This is a "connection" page, showing publications Christina Aquilante has written about Anticoagulants.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.377 |
|
|
|
-
Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006 Apr; 79(4):291-302.
Score: 0.174
-
Fahmi AM, El Bardissy A, Saad MO, Elshafei MN, Bader L, Mahfouz A, Kasem M, Abdelsamad O, Elzouki A, Aquilante CL, Mraiche F, Soaly E, El Madhoun I, Asaad N, Arabi A, Alhmoud E, Elewa H. Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial). Clin Transl Sci. 2024 06; 17(6):e13797.
Score: 0.154
-
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep; 84(3):326-31.
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|